Compare BridgeBio Pharma Inc (BBIO) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marriott International Inc — how do they compare? BridgeBio Pharma Inc trades at $82.99 (market cap $16.46B), while Marriott International Inc trades at $369.35 (market cap $95.77B). The key difference: Marriott International Inc is far larger — about 5.8× BridgeBio Pharma Inc's market cap, and Marriott International Inc pays a 0.8% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MAR | |
|---|---|---|
Market Cap | $16.46B | $95.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $402.54 |
52-Week Low | $44.81 | $255.35 |
Enterprise Value | $18.02B | $112.72B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Marriott International (MAR) trades at $362.87, down 3.52% today, with a bearish technical signal and mixed earnings history. The company maintains strong revenue growth, reaching $26.19B in 2025, and a net income margin of 9.72%. Recent developments include the launch of Ask Bonvoy AI and expansion to 10,000 properties, though debt levels have risen to 58.83% of assets. Analyst consensus is a $387.33 price target with 44% buy ratings.
The outlook is cautiously optimistic given solid fundamentals and strategic initiatives, but high valuation ratios and increasing leverage pose risks. Near-term performance hinges on Q2 2026 earnings due August 3, 2026, with investor focus on debt management and travel demand sustainability amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
